Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2018

Open Access 01-05-2018 | Original Article

Adipose tissue, but not skeletal muscle, sirtuin 1 expression is decreased in obesity and related to insulin sensitivity

Authors: Magdalena Stefanowicz, Agnieszka Nikołajuk, Natalia Matulewicz, Monika Karczewska-Kupczewska

Published in: Endocrine | Issue 2/2018

Login to get access

Abstract

Purpose

Sirtuin 1 may regulate glucose and lipid metabolism. We aimed to assess adipose tissue and skeletal muscle sirtuin 1 expression in relation to insulin sensitivity, the expression of proinflammatory and metabolic genes, and to study the regulation of sirtuin 1 expression by hyperinsulinemia and circulating free fatty acids elevation.

Methods

We examined 60 normal-weight, 42 overweight and 15 obese young subjects. The hyperinsulinemic-euglycemic clamp technique was applied throughout to measure insulin sensitivity. In 20 subjects, two 6 h clamps were performed, one of them with concurrent Intralipid/heparin infusion. Biopsies of subcutaneous adipose tissue and skeletal muscle were collected for the measurement of gene and protein expression.

Results

Obese subjects had lower adipose sirtuin 1 in comparison with normal-weight and overweight participants. Muscle sirtuin 1 did not differ between the groups. Adipose tissue sirtuin 1 was related to insulin sensitivity, adipose tissue SLC2A4. The relationship between adipose tissue sirtuin 1 and insulin sensitivity was still present after controlling for BMI, however, it disappeared after controlling for adipose tissue SLC2A4. Muscle sirtuin 1 was not related to insulin sensitivity. Hyperisulinemia decreased adipose tissue and increased muscle sirtuin 1 expression. Intralipid/heparin infusion negated these effects.

Conclusions

Adipose tissue, but not muscle, sirtuin 1 is associated with insulin sensitivity in humans, possibly because of its correlation with adipose tissue SLC2A4 expression. Insulin differentially regulates adipose tissue and skeletal muscle sirtuin 1 expression in the short-term and circulating free fatty acids elevation negates these effects, which may be associated with lipid-induced insulin resistance.
Appendix
Available only for authorised users
Literature
1.
S. Imai, C.M. Armstrong, M. Kaeberlein, L. Guarente, Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795–800 (2000)CrossRefPubMed
2.
S. Mariani, D. Fiore, S. Basciani, A. Persichetti, S. Contini, C. Lubrano, L. Salvatori, A. Lenzi, L. Gnessi, Plasma levels of SIRT1 associate with non-alcoholic fatty liver diseases in obese patients. Endocrine 49, 711–716 (2015)CrossRefPubMed
3.
F. Liang, S. Kume, D. Koya, SIRT1 and insulin resistance. Nat. Rev. Endocrinol. 5, 367–373 (2009)CrossRefPubMed
4.
S. Fröjdö, C. Durand, L. Molin, A.L. Carey, A. El-Osta, B.A. Kingwell, M.A. Febbraio, F. Solari, H. Vidal, L. Pirola, Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1. Mol. Cell. Endocrinol. 335, 166–176 (2011)CrossRefPubMed
5.
C. Sun, F. Zhang, X. Ge, T. Yan, X. Chen, X. Shi, Q. Zhai, SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell. Metab. 6, 307–319 (2007)CrossRefPubMed
6.
J. Zhang, The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J. Biol. Chem. 282, 34356–34364 (2007)CrossRefPubMed
7.
M.P. Gillum, M.E. Kotas, D.M. Erion, R. Kursawe, P. Chatterjee, K.T. Nead, E.S. Muise, J.J. Hsiao, D.W. Frederick, S. Yonemitsu, A.S. Banks, L. Qiang, S. Bhanot, J.M. Olefsky, D.D. Sears, S. Caprio, G.I. Shulman, SirT1 regulates adipose tissue inflammation. Diabetes 60, 3235–3245 (2011)CrossRefPubMedPubMedCentral
8.
T. Yoshizaki, J.C. Milne, T. Imamura, S. Schenk, N. Sonoda, J.L. Babendure, J.C. Lu, J.J. Smith, M.R. Jirousek, J.M. Olefsky, SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol. Cell. Biol. 29, 1363–1374 (2009)CrossRefPubMed
9.
A.S. Banks, N. Kon, C. Knight, M. Matsumoto, R. Gutiérrez-Juárez, L. Rossetti, W. Gu, D. Accilli, SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell. Metab. 8, 333–341 (2008)CrossRefPubMedPubMedCentral
10.
Z. Gerhart-Hines, J.T. Rodgers, O. Bare, C. Lerin, S.H. Kim, R. Mostoslavsky, F.W. Alt, Z. Wu, P. Puigserver, Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. Embo. J. 26, 1913–1923 (2007)CrossRefPubMedPubMedCentral
11.
S. Schenk, C.E. McCurdy, A. Philp, M.Z. Chen, M.J. Holliday, G.K. Bandyopadhyay, O. Osborn, K. Baar, J.M. Olefsky, Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction. J. Clin. Invest. 121, 4281–4288 (2011)CrossRefPubMedPubMedCentral
12.
J.N. Feige, M. Lagouge, C. Canto, A. Strehle, S.M. Houten, J.C. Milne, P.D. Lambert, C. Mataki, P.J. Elliott, J. Auwerx, Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 8, 347–358 (2008)CrossRefPubMed
13.
J.C. Milne, P.D. Lambert, S. Schenk, D.P. Carney, J.J. Smith, D.J. Gagne, L. Jin, O. Boss, R.B. Perni, C.B. Vu, J.E. Bemis, R. Xie, J.S. Disch, P.Y. Ng, J.J. Nunes, A.V. Lynch, H. Yang, H. Galonek, K. Israelian, W. Choy, A. Iffland, S. Lavu, O. Medvedik, D.A. Sinclair, J.M. Olefsky, M.R. Jirousek, P.J. Elliott, C.H. Westphal, Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712–716 (2007)CrossRefPubMedPubMedCentral
14.
M. Lagouge, C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, N. Messadeq, J. Milne, P. Lambert, P. Elliott, B. Geny, M. Laakso, P. Puigserver, J. Auwerx, Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109–1122 (2006)CrossRefPubMed
15.
S. Timmers, E. Konings, L. Bilet, R.H. Houtkooper, T. van de Weijer, G.H. Goossens, J. Hoeks, S. van der Krieken, D. Ryu, S. Kersten, E. Moonen-Kornips, M.K.C. Hesselink, I. Kunz, V.B. Schrauwen-Hinderling, E. Blaak, J. Auwerx, P. Schrauwen., Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14, 612–622 (2011)CrossRefPubMed
16.
L. Bordone, D. Cohen, A. Robinson, M.C. Motta, E. van Veen, A. Czopik, A.D. Steele, H. Crowe, S. Marmor, J. Luo, W. Gu, L. Guarente, SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 6, 759–767 (2007)CrossRefPubMed
17.
P.T. Pfluger, D. Herranz, S. Velasco-Miguel, M. Serrano, M.H. Tschop, Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl Acad. Sci. USA 105, 9793–9798 (2008)CrossRefPubMedPubMedCentral
18.
M. Karczewska-Kupczewska, I. Kowalska, A. Nikołajuk, A. Adamska, M. Zielińska, N. Kamińska, E. Otziomek, M. Górska, M. Strączkowski, Circulating brain-derived neurotrophic factor concentration is downregulated by intralipid/heparin infusion or high-fat meal in young healthy male subjects. Diabetes Care 35, 358–362 (2012)CrossRefPubMedPubMedCentral
19.
M. Karczewska-Kupczewska, M. Stefanowicz, N. Matulewicz, A. Nikołajuk, M. Strączkowski, Wnt signaling genes in adipose tissue and skeletal muscle of humans with different degrees of insulin sensitivity. J. Clin. Endocrinol. Metab. 101, 3079–3087 (2016)CrossRefPubMed
20.
E. Rappou, S. Jukarainen, R. Rinnankoski-Tuikka, S. Kaye, S. Heinonen, A. Hakkarainen, J. Lundbom, N. Lundbom, V. Saunavaara, A. Rissanen, K.A. Virtanen, E. Pirinen, K.H. Pietiläinen, Weight loss is associated with increased NAD(+)/SIRT1 expression but reduced PARP activity in white adipose tissue. J. Clin. Endocrinol. Metab. 101, 1263–1273 (2016)CrossRefPubMed
21.
S. Jukarainen, S. Heinonen, J.T. Rämö, R. Rinnankoski-Tuikka, E. Rappou, M. Tummers, M. Muniandy, A. Hakkarainen, J. Lundbom, N. Lundbom, J. Kaprio, A. Rissanen, E. Pirinen, K.H. Pietiläinen, Obesity is associated with low NAD(+)/SIRT pathway expression in adipose tissue of BMI-discordant monozygotic twins. J. Clin. Endocrinol. Metab. 101, 275–283 (2016)CrossRefPubMed
22.
S.B. Pedersen, J. Ølholm, S.K. Paulsen, M.F. Bennetzen, B. Richelsen, Low Sirt1 expression, which is upregulated by fasting, in human adipose tissue from obese women. Int. J. Obes. 32, 1250–1255 (2008)CrossRef
23.
Y.S. Song, S.K. Lee, Y.J. Jang, H.S. Park, J.H. Kim, Y.J. Lee, Y.S. Heo, Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes. Diabetes Res. Clin. Pract. 101, 341–348 (2013)CrossRefPubMed
24.
S.J. Clark, M. Falchi, B. Olsson, P. Jacobson, S. Cauchi, B. Balkau, M. Marre, O. Lantieri, J.C. Andersson, M. Jernås, T.J. Aitman, S. Richardson, L. Sjöström, H.Y. Wong, L.M. Carlsson, P. Froguel, A.J. Walley, Association of sirtuin 1 (SIRT1) gene SNPs and transcript expression levels with severe obesity. Obesity 20, 178–185 (2012)CrossRefPubMed
25.
S. Mariani, G. Di Rocco, G. Toietta, M.A. Russo, E. Petrangeli, L. Salvatori, Sirtuins 1-7 expression in human adipose-derived stem cells from subcutaneous and visceral fat depots: influence of obesity and hypoxia. Endocrine 57, 455–463 (2017)CrossRefPubMed
26.
J. Rutanen, N. Yaluri, S. Modi, J. Pihlajamäki, M. Vänttinen, P. Itkonen, S. Kainulainen, H. Yamamoto, M. Lagouge, D.A. Sinclair, P. Elliott, C. Westphal, J. Auwerx, M. Laakso, SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity. Diabetes 59, 829–835 (2010)CrossRefPubMedPubMedCentral
27.
N. Klöting, M. Fasshauer, A. Dietrich, P. Kovacs, M.R. Schön, M. Kern, M. Stumvoll, M. Bluher, Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299, E506–E515 (2010)CrossRefPubMed
28.
T. Nedachi, A. Kadotani, M. Ariga, H. Katagiri, M. Kanzaki, Ambient glucose levels qualify the potency of insulin myogenic actions by regulating SIRT1 and FoxO3a in C2C12 myocytes. Am. J. Physiol. Endocrinol. Metab. 294, E668–E678 (2008)CrossRefPubMed
29.
A.T. White, C.E. McCurdy, A. Philp, D.L. Hamilton, C.D. Johnson, S. Schenk, Skeletal muscle-specific overexpression of SIRT1 does not enhance whole-body energy expenditure or insulin sensitivity in young mice. Diabetologia 56, 1629–1637 (2013)CrossRefPubMedPubMedCentral
30.
A.E. Brandon, J. Tid-Ang, L.E. Wright, E. Stuart, E. Suryana, N. Bentley, N. Turner, G.J. Cooney, N.B. Ruderman, E.W. Kraegen, Overexpression of SIRT1 in rat skeletal muscle does not alter glucose induced insulin resistance. PLoS ONE 10, e0121959 (2015)CrossRefPubMedPubMedCentral
31.
A.T. White, A. Philp, H.N. Fridolfsson, J.M. Schilling, A.N. Murphy, D.L. Hamilton, C.E. McCurdy, H.H. Patel, S. Schenk, High-fat diet-induced impairment of skeletal muscle insulin sensitivity is not prevented by SIRT1 overexpression. Am. J. Physiol. Endocrinol. Metab. 307, E764–E772 (2014)CrossRefPubMedPubMedCentral
32.
E.D. Abel, O. Peroni, J.K. Kim, Y.B. Kim, O. Boss, E. Hadro, T. Minnemann, G.I. Shulman, B.B. Kahn, Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409, 729–733 (2001)CrossRefPubMed
33.
E. Carvalho, K. Kotani, O.D. Peroni, B.B. Kahn, Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. Am. J. Physiol. Endocrinol. Metab. 289, E551–E561 (2005)CrossRefPubMed
34.
C. Hofmann, K. Lorenz, J.R. Colca, Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 129, 1915–1925 (1991)CrossRefPubMed
35.
A.R. Moschen, V. Wieser, R.R. Gerner, A. Bichler, B. Enrich, P. Moser, C.F. Ebenbichler, S. Kaser, H. Tilg, Adipose tissue and liver expression of SIRT1, 3, and 6 increase after extensive weight loss in morbid obesity. J. Hepatol. 59, 1315–1322 (2013)CrossRefPubMed
36.
H.Y. Cohen, C. Miller, K.J. Bitterman, N.R. Wall, B. Hekking, B. Kessler, K.T. Howitz, M. Gorospe, R. de Cabo, D.A. Sinclair, Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305, 390–392 (2004)CrossRefPubMed
37.
A. Chalkiadaki, L. Guarente, High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab. 16, 180–188 (2012)CrossRefPubMedPubMedCentral
Metadata
Title
Adipose tissue, but not skeletal muscle, sirtuin 1 expression is decreased in obesity and related to insulin sensitivity
Authors
Magdalena Stefanowicz
Agnieszka Nikołajuk
Natalia Matulewicz
Monika Karczewska-Kupczewska
Publication date
01-05-2018
Publisher
Springer US
Published in
Endocrine / Issue 2/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1544-1

Other articles of this Issue 2/2018

Endocrine 2/2018 Go to the issue

Original Article

PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line

Endocrine Methods and Techniques

Shear wave elastography in the diagnostics of parathyroid adenomas–new application of the method

Original Article

Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients

Original Article

Impact of maternal thyroid autoantibodies positivity on the risk of early term birth: Ma’anshan Birth Cohort Study

Original Article

Association of obesity and diabetes with thyroid nodules

Original Article

Clinical study of pregnancy-associated fulminant type 1 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits